Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZomedicaZOMDF -4.79% 3-Year EBITDA Growth Rate is -9.50% as of Jun. 2026. The stock has 2 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Zomedica ranks worse than 76.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -9.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zomedica was 55.30% per year. The lowest was -117.90% per year. And the median was 0.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zomedica 3-Year EBITDA Growth Rate Related Terms
ZOMDF vs SERA, HYPR, OM: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Zomedica's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zomedica 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Zomedica's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -9.50% mean?
Zomedica (ZOMDF) has a 3-Year EBITDA Growth Rate of -9.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zomedica and its competitors. According to the industry distribution chart, Zomedica ranks #532 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 76.9%.
Is Zomedica's 3-Year EBITDA Growth Rate too high?
Zomedica's current 3-Year EBITDA Growth Rate is -9.50%. Based on the distribution chart, Zomedica ranks #532 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Zomedica's 3-Year EBITDA Growth Rate compare to SERA and HYPR?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #532 out of 692 companies for 3-Year EBITDA Growth Rate. This places Zomedica in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zomedica and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current 3-Year EBITDA Growth Rate is -9.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.08 — trading 53.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -9.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zomedica (ZOMDF), the current 3-Year EBITDA Growth Rate is -9.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZOMDF has been successfully added to your 
